Investors NewsSearch: Jun 18, 2025Rafael Holdings Announces Continuation of its Phase 3 Study for the Treatment of Niemann-Pick Disease Type C1 (NPC1) Following Independent Data Monitoring Committee (DMC) Review of Prespecified 48-Week Interim Data Jun 11, 2025Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results Jun 04, 2025Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering May 20, 2025Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ May 05, 2025Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ Apr 29, 2025Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™ Apr 24, 2025Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role Mar 26, 2025Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals Mar 13, 2025Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results Dec 11, 2024Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results 1 2 3 4 5 6 << < > >>
